To The Editor I read with interest the recent review by Okoshi and colleagues in the journal. This was a thoroughly enjoyable read that reviewed the main areas of focus. I would like, however, to reinforce some of the arguments. In the section on neurohormonal blockade there has also been a successful phase 2 trial of the fourth generation beta-blocker espindolol in cancer cachexia., Clearly beta-blockers can be helpful also in cardiac cachexia given their crucial role in heart failure […]